Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopeonol SCHEMBL3713802 | 1.00 | MAOB (0.57) | MAOBCAPN1MEN1KMT2APARP1 | |
| Isopeonol SCHEMBL29757918 | 1.00 | MAOB (0.57) | MAOBCAPN1MEN1KMT2APARP1 | |
| SCHEMBL1758262 | 0.86 | MAOB (0.58) | MAOBCAPN1MEN1KMT2APARP1 | |
| SCHEMBL21695849 | 0.84 | ALDH1A1 (0.47) | MAOBCAPN1MEN1KMT2APARP1 | |
| SCHEMBL901018 | 0.84 | ALDH1A1 (0.65) | MAOBCAPN1MEN1KMT2APARP1 | |
| SCHEMBL563973 | 0.84 | ALDH1A1 (0.56) | MAOBKMT2AALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4115468 | 0.82 | MAOB (0.55) | MAOBCAPN1MEN1KMT2APARP1 | |
| Methyl 4-Hydroxy-2-Methoxybenzoate SCHEMBL322895 | 0.82 | CA12 (0.67) | MAOBCAPN1MEN1KMT2APARP1 | |
| SCHEMBL9774402 | 0.81 | CA12 (0.50) | MAOBCAPN1MEN1KMT2APARP1 | |
| SCHEMBL9343430 | 0.81 | MEN1 (0.67) | MAOBCAPN1MEN1KMT2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115926-A1 | FORMULATION COMPRISING APOCYNIN AND PAEONOL | AKL RESEARCH & DEVELOPMENT LTD (GB) | 2024-06-06 | — | — | WO | disclosed |
| CN-116999417-A | Liquid preparation containing paeonol and apocynin | AKL研究发展有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230330017-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | AKL RES & DEVELOPMENT LTD (GB) | 2023-10-19 | — | — | US | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| CN-111372572-B | Liquid preparation containing paeonol and apocynin | AKL研究发展有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11701325-B2 | Liquid formulation comprising paeonol and apocynin | AKL RESEARCH & DEVELOPMENT LTD (GB) | 2023-07-18 | — | — | US | disclosed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-02-14 | — | — | US | disclosed |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-02-14 | — | — | US | disclosed |
| EP-4019005-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | AKL Research&Development Ltd (GB) | 2022-06-29 | — | — | EP | disclosed |
| EP-0395697-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4 | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1990-11-07 | — | — | EP | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4920133-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989004303-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| US-4810713-A | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0235463-A2 | N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-09-09 | — | — | EP | disclosed |
| EP-0113236-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES-PYRAZINES, AND -TRIAZINES | ELI LILLY AND COMPANY (US) | 1987-04-22 | — | — | EP | disclosed |
| US-4636502-A | Methods of producing a positive inotropic effect or vasodilation by administration of 2-phenyl imidazo pyrimidines and pyrazines | ELI LILLY AND COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
| US-4537889-A | PHENYL SUBSTITUTED IMIDAZO COMPOUNDS | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0113236-A1 | Substituted imidazopyrimidines-pyrazines, and -triazines | ELI LILLY AND COMPANY (US) | 1984-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701325-B2 | Liquid formulation comprising paeonol and apocynin | LPL, PNLIP, LPO | MAOB 48/4885CAPN1 910/4885MEN1 2821/4885 |
| US-20230330017-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | LPL, PNLIP, LPO | MAOB 48/4885CAPN1 910/4885MEN1 2821/4885 |
| US-11786524-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | MAOB 3590/4885CAPN1 1714/4885MEN1 1383/4885 |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | SLC10A1, GYS2, CPT1A | MAOB 644/4885CAPN1 4745/4885MEN1 918/4885 |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | AADAC, HDAC8, KAT8 | MAOB 176/4885CAPN1 1555/4885MEN1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.